{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:01:43Z","timestamp":1790949703644,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012482","name":"University of Michigan Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["P30CA046592"],"award-info":[{"award-number":["P30CA046592"]}],"id":[{"id":"10.13039\/100012482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Denosumab is an effective treatment for giant cell tumor of the bone (GCTB) but can cause clinically significant adverse effects. Current approved dosing is every 4 weeks after 3 weekly loading doses. We assessed whether alternative, longer dosing intervals are associated with differences in efficacy or bone toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Single institution retrospective chart review was conducted on patients with GCTB over 18 years old who received at least 1 year of standard denosumab dosing. Patients identified using a free-text search engine with keywords \u201cgiant cell tumor\u201d and \u201cdenosumab\u201d from January 1998 to August 2020.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Approximately 37 patients with GCTB (19F, 18M) were identified with median age of 37 years (range 22-73). Dosing interval was increased in 38% (n = 14), with the most common final dosing interval 12 weeks (n = 8). Six patients (16%) had bone complications: osteonecrosis of the jaw (n =5), atypical fracture (n = 1), and nonhealing dental wounds (n = 2). All patients with bone complications were on the monthly dosing schedule, but there was no statistically significant difference compared to longer dosing intervals (P = .22). No statistically significant difference in median PFS was noted (P = .97). However, 5-year PFS was superior in patients treated with less frequent versus standard dosing of denosumab (P = .036).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Increasing the interval of denosumab dosing for GCTB provided similar tumor control compared to standard dosing and lower absolute number of bone toxicity events. Larger studies are needed to better define the optimal interval of denosumab administration and the effect on efficacy, toxicity, and associated healthcare expense.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac066","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T19:20:33Z","timestamp":1650396033000},"page":"595-599","source":"Crossref","is-referenced-by-count":22,"title":["Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-1875","authenticated-orcid":false,"given":"Cindy Y","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-4163","authenticated-orcid":false,"given":"Scott M","family":"Schuetze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, University of Michigan Rogel Cancer Center , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-6971","authenticated-orcid":false,"given":"Rashmi","family":"Chugh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology\/Oncology, University of Michigan Rogel Cancer Center , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"2","key":"2022070520465873500_CIT0001","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5435\/JAAOS-21-02-118","article-title":"Giant cell tumor of bone.","volume":"21","author":"Raskin","year":"2013","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"2022070520465873500_CIT0002","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/17453674.2018.1490987","article-title":"Incidence and demographics of giant cell tumor of bone in The Netherlands: first nationwide Pathology Registry Study.","volume":"89","author":"Verschoor","year":"2018","journal-title":"Acta Orthop"},{"key":"2022070520465873500_CIT0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canep.2016.03.014","article-title":"Population-based study of giant cell tumor of bone in Sweden (1983-2011).","volume":"42","author":"Amelio","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"2022070520465873500_CIT0004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0038-1675815","article-title":"Giant cell tumor of bone: review of current literature, evaluation, and treatment options.","volume":"32","author":"Montgomery","year":"2019","journal-title":"J Knee Surg"},{"issue":"4","key":"2022070520465873500_CIT0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CCO.0000000000000529","article-title":"Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.","volume":"31","author":"Lipplaa","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"2022070520465873500_CIT0006","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000645","article-title":"Current concepts in the treatment of giant cell tumour of bone.","volume":"32","author":"van der Heijden","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"16","key":"2022070520465873500_CIT0007","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2022070520465873500_CIT0008","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2022070520465873500_CIT0009","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ejso.2018.03.020","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone\u2014multicenter analysis outside clinical trial.","volume":"44","author":"Rutkowski","year":"2018","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"2022070520465873500_CIT0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2022070520465873500_CIT0011","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","article-title":"Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.","volume":"51","author":"Gibiansky","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2022070520465873500_CIT0012","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2022070520465873500_CIT0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13569-016-0056-0","article-title":"Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone.","volume":"6","author":"Gaston","year":"2016","journal-title":"Clin. Sarcoma Res"},{"key":"2022070520465873500_CIT0014","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbi.2015.05.003","article-title":"Supporting information retrieval from electronic health records: A report of University of Michigan\u2019s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE)","volume":"55","author":"Hanauer","year":"2015","journal-title":"J Biomed Inform"},{"issue":"10","key":"2022070520465873500_CIT0015","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00402-019-03167-x","article-title":"Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature.","volume":"139","author":"Luengo-Alonso","year":"2019","journal-title":"Arch Orthop Trauma Surg"},{"key":"2022070520465873500_CIT0016","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2017.01.028","article-title":"Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?.","volume":"76","author":"Palmerini","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"2022070520465873500_CIT0017","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","article-title":"Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.","volume":"24","author":"Stopeck","year":"2016","journal-title":"Support Care Cancer"},{"issue":"7","key":"2022070520465873500_CIT0018","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2022070520465873500_CIT0019","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1007\/s00520-020-05719-z","article-title":"Financial toxicity and employment status in cancer survivors. A systematic literature review.","volume":"28","author":"Mols","year":"2020","journal-title":"Support Care Cancer"},{"key":"2022070520465873500_CIT0020","article-title":"Amgen.","author":"Xgeva Financial Resources."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/595\/44418244\/oyac066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/595\/44418244\/oyac066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T20:47:34Z","timestamp":1657054054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/7\/595\/6589501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,5,19]]},"published-print":{"date-parts":[[2022,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac066","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,5,19]]}}}